Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Diego
With
National Institute on Drug Abuse (NIDA)
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Aged 18-65
2. Possess the capacity to provide informed consent to a set of neurobehavioral, neuromedical and cognitive assessment procedures. Individuals unable to provide such consent will not be enrolled into the study.
3. Willing to confirm self-reported HIV using a rapid test: HIV status will be determined using the MedMira Rapid Test (Halifax, Nova Scotia, Canada). If the result differs from the participant's self-report a confirmatory Western Blot will be performed.
4. Willing to abstain from cannabis for at least 1 week prior to the baseline visit and during the study. Although there is no definitive method for determining abstinence over this period, abstinence will be confirmed as best as possible by using an oral fluid testing device (Draeger 5000) employed by law enforcement officers to detect recent cannabis use. An oral fluid value of \> 5ng suggests recent use, although in some cases it has been reported that individuals may show \> 5ng up to 20 hours after use. Thus, should the oral fluid sample indicate \> 5ng THC, the assessment may be canceled and rescheduled.
You may not be if
Inability to provide informed consent
Significant chronic renal disease (unrelated to HIV), significant chronic pulmonary disease (unrelated to HIV), or Hepatitis C Virus infection
Head injury with loss of consciousness for greater than 30 minutes or resulting in neurologic complications
Seizure disorder
Demyelinating diseases or other non-HIV neurological disorders
Pregnancy
Acute or recent or previous clinically disabling stroke or previous cerebrovascular events
Lifetime history of schizophrenia or other psychotic disorders, or bipolar disorder.
Beck Depression Inventory-II (BDI-II) score is greater than or equal to 29 (severe depression) or suicidal ideas are endorsed on the BDI-II or a Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation
Substance use disorder (mild, moderate or severe) within the last 12 months
